Lexicon Pharma (LXRX) Tops Q2 EPS by 5c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.04 --0%
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $376 million versus the consensus estimate of $360 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
